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A B S T R A C T
Background
Non-specific cough is defined as non-productive cough in the absence of identifiable respiratory disease or known aetiology. It is com-
monly seen in paediatric practice. These children are treated with a variety of therapies including inhaled anti-cholinergic medications.
Objectives
To determine the efficacy of inhaled anti-cholinergic medications in the management of prolonged non-specific cough in children.
Search methods
The Cochrane Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE databases were searched. Relevant pharmaceutical
companies were contacted. The latest searches were carried out in April 2010.
Selection criteria
All randomised controlled trials comparing inhaled anti-cholinergic medication with a placebo medication.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. No eligible trials were identified and thus no data were
available for analysis. A single small trial in adults has been reported.
Main results
No randomised-controlled trials that examined the efficacy of inhaled anti-cholinergic medications in the management of prolonged
non-specific cough in children were found. An additional search in April 2010 did not identify any further studies.
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Authors’ conclusions
There is currently no evidence to support the use of inhaled anti-cholinergics for symptomatic control of non-specific cough in children.
Further research examining the effects of this intervention is needed.
P L A I N L A N G U A G E S U M M A R Y
Anticholinergics for prolonged non specific cough in children
Children with non-specific cough, (non-productive cough in the absence of identifiable chest disease) are commonly treated with a
variety of medications for control of cough symptoms. This review examined the effect of inhaled anti-cholinergic drugs in children
with non-specific cough. Currently there is no evidence to support the use of inhaled anti-cholinergics as no randomised-controlled
trials of inhaled anti-cholinergic medications in the management of prolonged non-specific cough in children were found.
B A C K G R O U N D
Cough is a very common symptom of respiratory disease and the
commonest symptom for presentation to family doctors [Britt
2002]. The definition of chronic cough in children varies from
longer than 3 weeks to longer than 6 weeks. Prevalence ranges
from 3% in Dutch school children [Spee-van 1998] to 35% in
South African children [Nriagu 1999]. However, the reporting of
isolated cough in questionnaires is however unreliable [Brunekreef
1992] and prevalence figures are probably inaccurate.
Non-specific cough is defined as non-productive cough in the ab-
sence of identifiable respiratory disease or known aetiology [Chang
2001]. Children with a history of nonspecific cough are com-
monly seen in paediatric practice. The majority have no signs of
other current disease processes. In the absence of research to guide
clinical practice, these children are treated with a variety of ther-
apies: antibiotics, cough suppressants, anti-histamines, deconges-
tants, bronchodilators, anticholinergics, sodium cromoglycate, in-
haled corticosteroids and oral corticosteroids. These interventions
sometimes result in significant side effects [Thomson 2002].
Children with non-specific cough present a major management
problem and cause considerable anxiety to parents. The desire by
patients and medical practitioners to treat cough is reflected in
the wide use of over-the-counter (OTC) medications for coughs
and the frequent prescription of antibiotics for upper respiratory
tract infection [McManus 1997].Many childrenwith non-specific
cough are treated with asthma type medications (corticosteroids
and/or bronchodilators). However, beneficial effects of these in-
terventions have not been clearly described.
A Cochrane Review on the use of beta2-agonists for acute bron-
chitis focused on acute cough (undefined time frame) in adults
and children. The reviewers concluded that use of beta2-agonists
confers no benefit in the absence of airflow obstruction [Smucny
2006]. This present review focuses on prolonged non-specific
cough in children. This condition is most likely to differ from
acute bronchitis with respect to the duration of cough (>3 weeks)
and the quality of cough (non-productive).
O B J E C T I V E S
To determine the efficacy of inhaled anti-cholinergic medications
in treating children with non-specific cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing inhaled anti-choliner-
gic medications with a placebo medication.
Types of participants
All trials which included children under 18 years of age with pro-
longed (3 or more weeks) non-specific cough (dry and non-pro-
ductive cough without any other respiratory symptom, sign or
systemic illness). An a priori subgroup analysis was planned for
children aged < 7 years.
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Exclusion criteria: cough related to mycoplasma, pertussis and
chlamydia, presence of underlying cardio-respiratory condition,
current or recurrent wheeze (>2 episodes), presence of other res-
piratory symptoms (productive cough, haemoptysis, dyspnoea),
presence of other respiratory signs (clubbing, chest wall deformity,
respiratory noises such as wheeze on auscultation and other ad-
ventitious sounds), presence of any sign of systemic illness (failure
to thrive, aspiration, neurological or developmental abnormality),
presence of lung function abnormality.
Types of interventions
All randomised controlled comparisons of anti-cholinergic med-
ications versus placebo medication in the management of non-
specific cough. Trials only comparing two or more asthma med-
ications without a placebo comparison group were not included.
Two separate treatment regimes were evaluated:
1. Inhaled anticholinergic medications by metered dose
inhaler (with or without spacer device),
2. Inhaled anticholinergic medications by nebuliser
Trials that included the use of other medications or interventions
were included if all participants had equal access to such medica-
tions or interventions.
Types of outcome measures
Attempts were made to obtain data on at least one of the following
outcome measures:
Primary outcomes
a) proportions of participants who were not cured or not substan-
tially improved at follow up (clinical failure).
Secondary outcomes
b) proportions of participants who were not cured at follow up,
c) proportions of participants who not substantially improved at
follow up,
d)meandifference in cough indices (cough diary, cough frequency,
cough scores),
e) proportions experiencing adverse effects, e.g.. tremor, behavioral
changes (side effects),
f ) proportions experiencing complications e.g.. requirement for
medication change.
g) proportions of participants expressing preference formedication
or placebo.
h) proportions of parent/carers expressing preference for medica-
tion or placebo.
The proportions of participants who failed to improve on treat-
ment and the mean clinical improvement were determined using
the following hierarchy of assessment measures (i.e.. where two
or more assessment measures are reported in the same study, the
outcome measure that was listed first in the hierarchy was used).
1. Objective measurements of cough indices (cough
frequency, cough receptor sensitivity, cough amplitude).
2. Symptomatic (Likert scale, visual analogue scale, level of
interference of cough, cough diary) - assessed by the child.
3. Symptomatic (Likert scale, visual analogue scale, level of
interference of cough, cough diary) - assessed by the parents/
carers.
4. Symptomatic (Likert scale, visual analogue scale, level of
interference of cough, cough diary) - assessed by clinicians.
5. Airway markers consistent with infection or inflammation.
Search methods for identification of studies
The following topic search strategy was used to identify relevant
randomised controlled trials:
(cough [MeSH] OR cough [text word] OR bronchitis [MeSH]
OR bronchitis [text word]) AND (bronchodilator [MeSH] OR
bronchodilator [text word] or anti cholinergic [MeSH] OR anti-
cholinergic [text word] OR ipratropium [text word] OR ipra-
tropium bromide [text word]). The full strategies are listed in
Appendix 1. The latest searches were carried out in April 2010.
Trials were identified from the following sources:
1. The Cochrane Register of Controlled Trials (CENTRAL)
(which includes the Airways Collaborative Review Group
Specialised Trials Register).
2. MEDLINE 1966-current. Topic search strategy combined
with the MEDLINE randomised controlled trial search filter as
outlined in the Airways Group module.
3. OLDMEDLINE 1950-1965. Topic search strategy
combined with the MEDLINE randomised controlled trial
search filter as outlined in the Airways Group module.
4. EMBASE 1980-current. Topic search strategy combined
with the EMBASE randomised controlled trial search filter as
outlined in the Airways Group module.
5. Reference lists in relevant publications.
6. Written communication with the authors of trials included
in the review.
7. Written communication with major pharmaceutical
companies (with offices in Australia) that manufacture
anticholinergic medications.
Data collection and analysis
Retrieval of studies: Abstracts of papers identified from the search
were read by both reviewers (ABC, PM) who then independently
reviewed potentially relevant trials for full review. Searches of bibli-
ographies and texts were conducted to identify additional studies.
In additionABCwrote tomanufacturers of ipratropiumwith links
in Australia. It was planned that agreement would be measured
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using kappa statistics and disagreement resolved by consensus or
third party adjudication (M McKean).
Planned data analysis:
Trials that satisfied the inclusion criteria would have been re-
viewed and the following information recorded: study setting, year
of study, source of funding, patient recruitment details (includ-
ing number of eligible children), inclusion and exclusion criteria,
randomisation and allocation concealment method, numbers of
participants randomised, blinding (masking) of participants, care
providers and outcome assessors, dose and type of anti-choliner-
gic therapy, duration of therapy, co-interventions, numbers of pa-
tients not followed up, reasons for withdrawals from study proto-
col (clinical, side-effects, refusal and other), details on side-effects
of therapy, and whether intention-to-treat analyses were possible.
Data would have been extracted on the outcomes described pre-
viously. Further information would have been requested from the
authors where required.
Studies included in the review would have undergone quality as-
sessment performed independently by all reviewers. Four compo-
nents of quality would have been assessed:
1. Allocation concealment. Trials scored as: Grade A:
Adequate concealment, Grade B: Unclear, Grade C: Clearly
inadequate concealment. (Grade A = high quality).
2. Blinding. Trials scored as: Grade A: Participant and care
provider and outcome assessor blinded, Grade B: Outcome
assessor blinded, Grade C: Unclear, Grade D: No blinding of
outcome assessor (Grade A, B = high quality).
3. Reporting of participants by allocated group. Trials scored
as: Grade A: The progress of all randomised children in each
group described, Grade B: Unclear or no mention of withdrawals
or dropouts, Grade C: The progress of all randomised children
in each group clearly not described. (Grade A = high quality).
4. Follow-up. Trial scored as: Grade A: Outcomes measured in
>90% (where withdrawals due to complications and side-effects
are categorised as treatment failures), Grade B: Outcomes
measured in 80-90%, Grade C: Unclear, Grade D: Outcomes
measured in <80%. (Grade A = high quality).
While only the allocation concealment quality assessment would
have been displayed in the meta-analysis figures, all assessments
would have been included in the “Characteristics of included stud-
ies” table. Inter-reviewer reliability for the identification of high
quality studies for each component would have been measured by
the Kappa statistic.
For the dichotomous outcome variables of each individual study,
relative and absolute risk reductions would have been calculated
using a modified intention-to-treat analysis. This analysis assumes
that children not available for outcome assessment have not im-
proved (and probably represents a conservative estimate of effect).
An initial qualitative comparison of all the individually analysed
studies would have examined whether pooling of results (meta-
analysis) was reasonable. This would take into account differences
in study populations, inclusion/exclusion criteria, interventions,
outcome assessment, and estimated effect size.
The results from studies that met the inclusion criteria and re-
ported any of the outcomes of interest would have been included
in the subsequent meta-analyses. The summary weighted risk ra-
tio and 95% confidence interval (fixed effects model) were to be
calculated using the inverse of the variance of each study result
for weighting (Cochrane statistical package, REVMAN version
5). The number needed to treat was to be calculated using the
summary odds ratio and the average control event rate described
in the relevant studies. The cough indices were to be assumed to
be normally distributed continuous variables so the mean differ-
ence in outcomes can be estimated (weighted mean difference).
If studies reported outcomes using different measurement scales,
the standardised mean difference was to be estimated. Any hetero-
geneity between the study results was to be described and tested
to see if it reached statistical significance using a chi-squared test
(where p< 0.1 is considered significant). The 95% confidence in-
terval estimated using a random effects model was to be included
whenever there are concerns about statistical heterogeneity.
An a priori sub-group analysis was planned for children less than 7
years of age. Sensitivity analyses were planned to assess the impact
of the potentially important factors on the overall outcomes: a)
study quality; b) study size; c) variation in the inclusion criteria;
d) differences in the medications used in the intervention and
comparison groups; e) differences in outcomemeasures; f ) analysis
by standard intention-to-treat (children not available for outcome
assessment not included) rather than modified intention-to-treat,
and g) analysis by “treatment received (children not available for
outcome assessment and childrenwho did not receive intervention
in accordance with protocol not included) rather than modified
”intention-to-treat“.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
The searches identified 4 potential studies but all did none fulfilled
the study eligibility criteria.
Risk of bias in included studies
Not applicable
Effects of interventions
The Airways Group specialised register/search identified 864 po-
tentially relevant titles. After assessing the abstracts, only 4 stud-
ies were considered for inclusion into review. Three other studies
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were further identified from the additional sources. None of the
studies fulfilled study criteria. One study did evaluate the effec-
tiveness of an inhaled anti-cholinergic medication in prolonged
non-specific cough but only included adults [Holmes 1992]. Ad-
ditional searches in subsequent years (April 2004, 2005, 2006,
2007, 2008, 2009 and 2010) did not identify any further studies.
One study that used nasal ipratropium (for ’colds’) was excluded
as it did not meet the inclusion criteria of the review.
D I S C U S S I O N
No randomised controlled trials of inhaled anti-cholinergic med-
ications for the treatment of persistent non-specific cough in chil-
dren were identified. A small randomised, double blind, crossover
trial involving 14 adults with persistent cough following a viral
infection has been conducted [Holmes 1992]. The investigators
reported an overall clinical improvement and reduction in cough
scores in the participants while they were receiving ipratropium
bromide (4 puffs of 20 micrograms, four times daily).
At this point, routine use of inhaled anti-cholinergic medications
cannot be recommended for children. Parents requesting a trial
of therapy should be informed of the lack of any well-designed
studies assessing effectiveness, the associated cost of treatment,
and the risk of side-effects. The manufacturer of first inhaled anti-
cholinergic medications indicated that none of their anti-cholin-
ergic medications are indicated for treatment of cough in children.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no evidence to support the use of inhaled anti-
cholinergics in children with non specific cough. The known ad-
verse events (e.g. paradoxical bronchospasm, paralytic ileus, tachy-
cardia) must also be considered if inhaled cholinergics medications
are used.
Implications for research
Randomised controlled studies to determine the effectiveness of
inhaled anti-cholinergic medications for symptomatic control of
cough in children with non specific cough are needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dicpinigaitis 2008 Study in adults with acute cough associated with a viral infection
Graf 2009 This review assesses two widely used intranasal treatments for nasal congestion and rhinorrhea in the common
cold: xylometazoline hydrochloride and ipratropium bromide. Thus does not fit into criteria of non-specific
chronic cough
Holmes 1992 Study on 14 adults with post viral infective cough
Lowry 1994 Study on 56 adults with cough associated with cold
Pulejo 1986 Cough associated with classical asthma and thus does not fit into criteria of non-specific chronic cough
Shore 1981 Non randomised report
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Database Search Strategies
CENTRAL
#1 COUGH
#2 BRONCHITIS
#3 cough*
#4 bronchit*
(#1 or #2 or #3 or #4)
#5 CHOLINERGIC ANTAGONISTS
#6 (anticholinergic* or anti-cholinergic*)
#7 ipratropium
#8 (cholinergic* near antagonist*)
#9 (cholinergic* near block*)
#10 (acetylcholine or cholinolytic*)
#11 (atrovent or aerocap* or aerohaler* or autohaler* or respontin or tropiovent)
#12 (#6 or #7 or #8 or #9 or #10 or #11 or #12)
#13 (#5 and #13)
MEDLINE
1. exp Cough/
2. exp Bronchitis/
3. cough$.mp.
4. bronchit$.mp.
5. 1 or 2 or 3 or 4
6. exp Cholinergic Antagonists/
7. (anticholinergic$ or anti-cholinergic$).mp.
8. Ipratropium.mp.
9. (cholinergic$ adj3 antagonist$).mp.
10. (cholinergic$ adj3 block$).mp.
11. (acetylcholine or cholinolytic$).mp.
12. (Atrovent or Aerocap$ or Aerohaler$ or Autohaler$ or Respontin or Tropiovent).mp.
13. 6 or 7 or 8 or 9 or 10 or 11 or 12
14. 5 and 13
EMBASE
1. exp Coughing/
2. cough$.mp.
3. exp BRONCHITIS/
4. bronchit$.mp.
5. 1 or 2 or 3 or 4
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6. exp Cholinergic Receptor Blocking Agent/
7. (anticholinergic$ or anti-cholinergic$).mp.
8. exp Ipratropium Bromide/
9. (cholinergic$ adj3 antagonist$).mp.
10. (cholinergic$ adj3 block$).mp.
11. (acetylcholine or cholinolytic$).mp.
12. (Ipratropium or Atrovent or Aerocap$ or Aerohaler$ or Autohaler$ or Respontin or Tropiovent).mp.
13. 6 or 7 or 8 or 9 or 10 or 11 or 12
14. 5 and 13
WH A T ’ S N E W
Last assessed as up-to-date: 13 April 2010.
Date Event Description
14 April 2010 New search has been performed New search. No new studies found
26 January 2010 Amended Reporting of search dates in abstract corrected.
H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 4, 2003
Date Event Description
10 May 2009 New search has been performed New search - no relevant studies found
24 March 2009 Amended Change of contact details
5 April 2008 Amended Converted to new review format.
1 April 2008 Amended Search re-run; no new trials eligible for inclusion in the
review
21 July 2003 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
ABC and PM wrote the protocol, review and independently reviewed potential abstracts and papers. MM contributed to final protocol
and review
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
• National Health and Medical Research Council, Australia.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Cholinergic Antagonists [∗therapeutic use]; Cough [∗drug therapy]
MeSH check words
Child; Humans
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